VIA MEDICA

EDITORIAL

Cardiology Journal
2024, Vol. 31, No. 3, 367–368
DOI: 10.5603/cj.94330
Copyright © 2024 Via Medica
ISSN 1897–5593
eISSN 1898–018X

Current understanding of Duchenne muscular dystrophy — a purported interview with a purported expert

Jarosław Meyer-Szary[1], Szymon Mikulski[2]

[1]Department of Pediatric Cardiology and Congenital Heart Diseases, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland
[2]Department of Head and Neck Surgery, Singapore General Hospital, Singapore

Q1. What is Duchenne muscular dystrophy (DMD)?

A1. It is the most common form of muscular dystrophy in children. It is estimated to affect 1 in every 3500 to 5000 male births worldwide. DMD is a genetic disorder caused by mutations in the dystrophin gene responsible for producing the protein dystrophin. Dystrophin is a protein found in muscle cells that helps keep them strong and functioning properly. The lack of dystrophin leads to progressive muscle degeneration, resulting in a variety of symptoms, including muscle weakness, contractures, cardiomyopathy, and difficulty in breathing. The disorder is progressive, typically diagnosed in early childhood, and is associated with a shortened lifespan.

Q2. What are the symptoms of DMD?

A2. The symptoms of DMD vary depending on the age of the individual, but generally include muscle weakness, difficulty walking, and difficulty climbing stairs. As the disease progresses, the individual may experience difficulty standing, and eventually require the use of a wheelchair. Other common symptoms include muscle wasting, joint contractures, difficulty swallowing, difficulty breathing, and heart failure. In some cases, individuals may also experience cognitive impairment, seizures, and scoliosis.

Q3. What are the causes of DMD?

A3. DMD is caused by mutations in the dystrophin gene, which is located on the X chromosome. The dystrophin gene is responsible for producing the protein dystrophin, which is necessary for muscle cells to function properly. Mutations in this gene cause the body to produce an abnormal or non-functioning dystrophin protein, which leads to the muscle weakness.

Q4. How is DMD diagnosed?

A4. DMD is typically diagnosed through a combination of clinical examination, muscle biopsy, and genetic testing. During the clinical examination, a doctor will look for signs of muscle weakness, joint contractures, and other abnormalities. Both genetic testing and a muscle biopsy can be used to confirm the diagnosis with the former able to identify specific mutations in the dystrophin gene. In some cases, other tests such as an electromyogram (EMG) or a nerve conduction study may be used to help diagnose DMD.

Q5. What treatments are available for DMD?

A5. Currently, there is no cure for DMD, but there are a number of treatments available to help manage the symptoms and slow the progression of the disease. The primary treatment for DMD is corticosteroid therapy, which is used to reduce muscle inflammation and slow the progression of the disorder. The most commonly used corticosteroid is prednisone, which has been shown to improve muscle strength and function in those with DMD. Additionally, long-term use of corticosteroids has been associated with a reduced risk of scoliosis, cardiomyopathy, and respiratory complications.

Address for correspondence: Jarosław Meyer-Szary, Department of Pediatric Cardiology and Congenital Heart Diseases, Faculty of Medicine, Medical University of Gdansk, Skłodowskiej-Curie 3a St., 80–210, Gdansk, Poland, tel: +48 583492882; e-mail: jmeyerszary@gumed.edu.pl

Received: 21.02.2023 Accepted: 10.04.2024

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

Physical therapy is an important component of DMD treatment and is used to improve muscle strength, reducing fatigue and function, and improving balance and coordination. It can also help to reduce the risk of contractures and scoliosis. Orthopedic surgery is sometimes used to treat severe contractures or scoliosis. These surgeries can help to improve range of motion and reduce pain.

Cardiac care is an important component of DMD treatment, as the disorder is associated with an increased risk of cardiomyopathy. It typically includes regular monitoring and medication to reduce the risk of complications and manage heart failure.

Respiratory management strategies for DMD involve a combination of medical and physical therapy. Medically, bronchodilators and steroids may be used to reduce airway inflammation and improve airway function. Oxygen therapy can also be used to increase oxygen levels in the body. Physically, regular exercise and postural drainage techniques can help maintain pulmonary function. Additionally, respiratory rehabilitation programs may be employed to provide education and training on how to better manage shortness of breath and other symptoms. Nocturnal assisted breathing devices such as continuous positive airway pressure (CPAP) machines and bi-level positive airway pressure (BiPAP) machines can help stabilize breathing during sleep and reduce the risk of respiratory infections. Mechanical ventilation may also be necessary to maintain adequate oxygen levels in the body and to prevent complications such as respiratory failure.

Psychosocially, psychological support can help manage the emotional and cognitive effects of the condition.

Gene therapy is a promising treatment for DMD, but it is still in the early stages of development. The goal of gene therapy is to replace the mutated dystrophin gene with a healthy version, which could potentially restore muscle function. While gene therapy is still in the early stages of development, it has shown promise in animal models, and clinical trials are currently underway.

Q6. What is the prognosis for individuals with DMD?

A6. The prognosis varies depending on the severity of the disease and the age at which it is diagnosed. Most individuals with DMD will require the use of a wheelchair by the age of 12, and the average life expectancy is around 25 years.

Q7. What research is being done to find a cure for DMD?

A7. Currently, there is a great deal of research being done to find a cure for DMD. This research includes gene therapy, stem cell therapy, and medications to help manage the symptoms of DMD. A number of treatments are already in various phases of clinical trials. Additionally, researchers are looking at ways to improve the quality of life for individuals with DMD, such as developing assistive devices and improving physical therapy and occupational therapy techniques.

Q8. Are there any support groups or resources available for individuals with DMD?

A8. Yes, there are a number of support groups and resources available for individuals with DMD. These include local and online support groups, and national organizations such as the Muscular Dystrophy Association (MDA) or Parent Project Muscular Dystrophy (PPMD). Additionally, there are a number of websites and blogs dedicated to providing information and support.

Q9. What advice would you give to parents of a child with DMD?

A9. The most important advice I would give to parents of a child with DMD is to seek out support and resources. It is important to connect with other families who have a child with DMD, as well as local organizations. Additionally, it is important to stay informed about the latest research and treatments available for DMD, and to make sure that your child is receiving the best possible care. Finally, it is important to remember that each child is unique and to focus on the positive aspects of their life, such as their strengths and abilities.

— Thank you for the interview.

— Thank you for having me.

Disclosure

This article is fully written by artificial intelligence using GTP-3.5 large language model. However, the concept, prompt engineering, fact-checking, and final editing were human input. For the writing of this article, we have not received funds or support from OpenAI or any other company. Please refer to the companion commentary on pages 369–373 of this issue for relevant discussion.